Scholar Rock wins FDA approval for first drug to target SMA muscle loss Late-stage trial finds therapy improves young patients’ motor skills By Jonathan WosenSept. 11, 2026 West Coast Biotech & Life Sciences Reporter

https://www.statnews.com/2026/09/11/scholar-rock-spinal-muscular-atrophy-isembyld-clinical-trial-fda-approval/